ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Monday, November 13, 2023

9:00AM-11:00AM: Abstract Number: 0938

Deconvolution of the Molecular Signature of Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Established Disease: A Biomarker Blueprint of Scleroderma Disease Continuum

(0934–0964) Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1560

Decreased Level of Peripheral CLA+ Treg Is a Protective Factor of Nervous System Involvement in Behcet’s Syndrome: A Real-World Study in China

(1554–1578) Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

9:00AM-11:00AM: Abstract Number: 1495

Deep Serological Profiling of SLE Patients Treated with anti-CD19 CAR T Cells

(1488–1512) SLE – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 0881

Deficiency of the Pattern-recognition Receptor CD14 Protects Against LPS-induced Inhibition of Osteoclastogenesis in Vitro

(0859–0885) Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1407

Defining Thresholds of Presenteeism Measures for Unacceptable Work Participation in axSpA

(1383–1411) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Imaging & AS

9:00AM-11:00AM: Abstract Number: 1355

Delivering Care for Pregnant Women with Rheumatic and Musculoskeletal Diseases in Ireland: Current Challenges and Practices

(1345–1364) Reproductive Issues in Rheumatic Disorders Poster II

9:00AM-11:00AM: Abstract Number: 1373

Deltex1 May Involve the Function of T Regulatory Cells and Regulate the Disease Activity of Sjögren’s Syndrome

(1365–1382) Sjögren’s Syndrome – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 1480

Demographic and Clinical Characteristics of Patients with LN: A Multicenter Study from the Gulf Region

(1442–1487) SLE – Diagnosis, Manifestations, & Outcomes Poster II

9:00AM-11:00AM: Abstract Number: 1263

Depression and Anxiety Risk Assessment in Patients with Rheumatic Diseases

(1256–1263) Psychology/Social Science – Interprofessional Poster

9:00AM-11:00AM: Abstract Number: 1158

Dermatomyositis Flares After COVID-19 Vaccination and/or SARS-CoV-2 Infection

(1155–1182) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 1211

Description of Self-Efficacy for Managing Symptoms and Emotions in a Large Rheumatology Clinic Population

(1200–1220) Patient Outcomes, Preferences, & Attitudes Poster II

9:00AM-11:00AM: Abstract Number: 1144

Deucravacitinib in Plaque Psoriasis: Maintenance of Response over 3 Years

(1124–1154) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

9:00AM-11:00AM: Abstract Number: 1290

Development of a Genetic Risk Score for Pain in Rheumatoid Arthritis

(1264–1307) RA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-11:00AM: Abstract Number: 1188

Development of a Method to Isolate Functional Mitochondria and Assess Their Functionality and Integration in Joint Tissues: In Vitro and in Vivo Models

(1183–1199) Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1093

Development of Adaptive Immunity Against Different SARS-CoV-2 Variants over the Course of Three COVID-19 Vaccinations in Patients with Inflammatory Rheumatic Diseases

(1082–1099) Measures & Measurement of Healthcare Quality Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].